Sino-US tensions engendered by US president Donald Trump are driving each US and Chinese language biotech companies, in addition to biotech companies headquartered elsewhere, to checklist on the Hong Kong Inventory Alternate (HKEX) as an alternative of Nasdaq, previously thought to be the premier preliminary public providing (IPO) vacation spot of biotechs, in response to audio system at a latest BIOHK convention in Hong Kong.
¬ Haymarket Media Restricted. All rights reserved.